Skip to content

Exploring the biological characteristics of refractory rheumatoid arthritis based on multi omics analysis

Exploring the biological characteristics of refractory rheumatoid arthritis based on multi omics analysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110225
Enrollment
Unknown
Registered
2025-10-10
Start date
2024-10-13
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Normal group:None
Non refractory rheumatoid arthritis group:None
Refractory rheumatoid arthritis group:None

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meets the Western diagnostic criteria for rheumatoid arthritis; 2. Meet the diagnostic criteria for refractory rheumatoid arthritis set by the European Union Against Rheumatism; 3. Meet the criteria for active rheumatoid arthritis, i.e. DAS28>3.2; 4. Age >= 18 years old; 5. The subjects agree to join this study and sign an informed consent form;

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver and kidney dysfunction; 2. Patients with severe primary diseases of cardiovascular, pulmonary, renal, endocrine, and hematopoietic systems; 3. Have a history of hepatitis B, hepatitis C, tuberculosis, AIDS, acquired immunodeficiency syndrome (AIDS) or malignant tumor; 4. Patients with combined inflammatory arthritis diseases such as psoriatic arthritis, ankylosing spondylitis, and gouty arthritis; 5. Individuals with mental illnesses who lack self-awareness and are unable to express themselves accurately; 6. Pregnant, lactating women or those preparing for pregnancy; 7. Patients who are currently participating or have participated in other clinical trials within the past month; 8. Researchers have determined that patients have poor compliance and are unable to complete the trial.

Design outcomes

Primary

MeasureTime frame
Biomarkers;

Secondary

MeasureTime frame
erythrocyte sedimentation rate;C-reactive protein;rheumatoid factor;Rheumatoid antibodies;

Countries

China

Contacts

Public ContactWei Liu

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

fengshiliuwei@163.com+86 135 1616 1000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026